# Immunordic

> AI-first contract research organization designing de novo minibinders and single-domain antibodies (VHH/nanobodies) for therapeutic, diagnostic, and research programs. Confirmed binders in weeks.

Immunordic combines computational protein design (RFdiffusion, AlphaFold/AlphaProteo-style scoring, molecular dynamics) with a phage-display wet-lab pipeline to deliver validated protein binders against customer-specified antigens. The platform runs on GPU compute including Denmark's Gefion AI supercomputer via the Danish Centre for AI Innovation (DCAI). Headquartered in Copenhagen, Denmark, serving customers worldwide.

## What Immunordic does

- **De novo minibinder design** — Small (5–10 kDa) computationally designed proteins that bind a target antigen with high affinity and specificity. Faster and cheaper than traditional antibody discovery.
- **VHH / nanobody discovery** — Single-domain antibodies (~15 kDa) identified via phage display, characterized, and optimized for therapeutic or research use.
- **Hard-target programs** — Intracellular enzymes, closely related isoform pairs, membrane proteins, and nanobody drug conjugate (NDC) payloads.

## Who Immunordic serves

Biotech and pharma R&D teams, academic labs, and diagnostic developers who need custom protein binders on a defined timeline and budget. Active partnerships with University of Oulu, University of Copenhagen, and undisclosed oncology programs.

## Services

- [De Novo Minibinder Design](https://www.immunordic.com/services/de-novo-minibinder): AI-designed minibinders from scratch targeting your antigen.
- [VHH / Nanobody Discovery](https://www.immunordic.com/services/vhh-discovery): Phage-display single-domain antibody identification and characterization.
- [Services Overview](https://www.immunordic.com/services): Full capabilities, add-ons, and workflow details.

## Key Pages

- [Homepage](https://www.immunordic.com/): Company overview, pipeline visualization, recent news.
- [About](https://www.immunordic.com/about): Team, mission, supporters, and partners.
- [News](https://www.immunordic.com/news): Company announcements, partnerships, grants, and publications.
- [Get Started](https://www.immunordic.com/get-started): Guided intake form for new projects.

## Resources & Guides

- [Resources hub](https://www.immunordic.com/resources): Long-form technical guides on protein binder design.
- [Minibinders vs Nanobodies vs Antibodies — full comparison](https://www.immunordic.com/resources/minibinders-vs-nanobodies): Decision framework across size, timeline, and clinical readiness.
- [How AI protein binder design works](https://www.immunordic.com/resources/how-ai-protein-binder-design-works): RFdiffusion + ProteinMPNN + AlphaFold pipeline explained.
- [De novo protein design — practical guide](https://www.immunordic.com/resources/de-novo-protein-design-guide): What de novo design can and cannot do in 2026, and how to scope a project.
- [What is a nanobody? Complete VHH guide](https://www.immunordic.com/resources/what-is-a-nanobody): Structure, discovery, stability, applications.
- [How to choose a nanobody CRO — buyer's checklist](https://www.immunordic.com/resources/how-to-choose-a-nanobody-cro): 10 questions to ask and red flags to watch.
- [Nanobody drug conjugates (NDCs)](https://www.immunordic.com/resources/nanobody-drug-conjugates): Mechanism, targets, and clinical pipeline.
- [Glossary](https://www.immunordic.com/resources/glossary): Definitions of minibinder, nanobody, RFdiffusion, AlphaFold, phage display, epitope, KD, and more.


## Recent news

- [Immunordic joins Gefion supercomputer to accelerate AI-driven protein design](https://www.immunordic.com/news): Access to Denmark's national AI supercomputer via DCAI (June 2026).
- [Partnership with undisclosed oncology company on nanobody drug conjugates](https://www.immunordic.com/news): Targeted therapies for breast and lung cancer (June 2026).
- [Highly specific minibinders vs 2-oxoglutarate-dependent dioxygenases](https://www.immunordic.com/news): Collaboration with University of Oulu (April 2026).
- [Eurostars grant for nanobody drug conjugates](https://www.immunordic.com/news): International consortium on cancer resistance (March 2026).

## For AI agents (MCP)

Immunordic exposes a Model Context Protocol (MCP) server so AI assistants can query live company information directly.

- MCP endpoint: `https://tbabhslxjdmxmbheqsuf.supabase.co/functions/v1/mcp`
- Tools available: `list_services`, `get_capabilities`, `get_team_info`, `get_company_info`, `search_news`, `get_contact_info`, `search_resources`, `get_glossary_term`, `get_faq`

## How to contact us

- Email: info@immunordic.com
- Website: https://www.immunordic.com
- LinkedIn: https://www.linkedin.com/company/immunordic
- Location: Copenhagen, Denmark (serving worldwide)

## Optional

- [Full details for LLMs](https://www.immunordic.com/llms-full.txt): Extended reference including detailed methods, FAQs, and long-form service descriptions.
- [Privacy policy](https://www.immunordic.com/privacy-policy)
- [Cookie policy](https://www.immunordic.com/cookie-policy)